Wave Life Sciences to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

Rhea-AI Summary

Wave Life Sciences Ltd. (Nasdaq: WVE) has announced that Paul Bolno, MD, MBA, the President and CEO, will present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020, at 11:30 a.m. ET. Investors can access a live webcast of the presentation on the company’s Investor Relations page. Wave Life Sciences focuses on developing life-changing genetic medicines for severe diseases using its proprietary PRISM platform, which allows for the precise design and production of stereopure oligonucleotides.

News Market Reaction – WVE

+11.38%

+11.38% Session move

In the trading session that priced this news, WVE gained 11.38%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to present at the H.C. Wainwright 22^nd Annual Global Investment Conference on Monday, September 14, 2020 at 11:30 a.m. ET.

A live webcast of the presentation will be available on the Investor Relations page of the Wave Life Sciences corporate website at http://ir.wavelifesciences.com. A replay of the presentation will be archived and available at that site for 90 days following the event.

About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company’s proprietary discovery and drug development platform that enables the precise design, optimization and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. To find out more, please visit www.wavelifesciences.com and follow Wave on Twitter @WaveLifeSci.

Investor Contacts:
Kate Rausch
617-949-4827
krausch@wavelifesci.com

Graham Morrell
781-686-9600
gmorrell@wavelifesci.com

Media Contact:
Alicia Suter
617-949-4817
asuter@wavelifesci.com

FAQ

When is Paul Bolno presenting at the H.C. Wainwright Conference for WVE?

Paul Bolno will present on September 14, 2020, at 11:30 a.m. ET.

How can I watch the live presentation for WVE?

The live webcast can be viewed on the Wave Life Sciences Investor Relations page.

What is the purpose of Wave Life Sciences' PRISM platform?

The PRISM platform is used for the precise design and production of stereopure oligonucleotides.

What type of company is Wave Life Sciences?

Wave Life Sciences is a clinical-stage genetic medicines company focused on developing treatments for severe diseases.